Used for: Non-small cell lung cancer with an EGFR gene change
How to pay the least
Ask for the cash price
Tagrisso
We didn’t find one.
What to do
Ask your pharmacy for Tagrisso’s cash price, and one or two other pharmacies too.
Tagrisso’s savings card works only with insurance from a job or one you bought.
Other ways
Free from the maker, if you qualify AZ&Me Prescription Savings Program. For AZ&Me’s Specialty and Primary products, your annual adjusted gross income must be at or below 300% of the Federal Poverty Level Or call 1-800-292-6363.
“Most eligible patients will pay as little as $0 per month and may have access to up to $26,000 per year to assist with TAGRISSO out-of-pocket costs…”
From the maker’s offer on tagrissohcp.com, checked October 27, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Maker’s card or discount card?
A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.
adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
the treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
in combination with pemetrexed and platinum-based chemotherapy, the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
the treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy.
Source: the FDA label for Tagrisso (AstraZeneca Pharmaceuticals LP), September 14, 2026. Full label on DailyMed
Good to know
“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.
Prices checked October 27, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/tagrisso/